Track topics on Twitter Track topics that are important to you
An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immune system, which makes it feasible to use asiRNA for the treatment of age-related macular degeneration, a disease to which RNAi therapeutics could not be developed using conventional siRNAs. Other potential applications for BMT's technology include therapeutics targeting infectious disease, such as herpes simplex virus (HSV), and cancer. A privately held company based in Suwon, South Korea, BMT was established in 2010.
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: PhD Scholarships Biomolecular Sciences .The doctoral program of CIBIO in Biom...
RSSL's biomolecular analysis group has relocated to expanded laboratories at its JJT facility at Reading University.
Reading Scientific Services Limited (RSSL) has relocated its biomolecular analysis group to expanded laboratories in its JTT facility on the Reading University site.
Life Sciences Jobs ...
Assistant Professor, Department of Biomolecular Engineering University of California, Santa Cruz. Age: 34
The innovative technique allows for the imaging of up to 24 biomolecular structures at a time instead of being limited by only five fluorescent proteins
Summit Therapeutics PLC and Orexigen Therapeutics are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, in...
CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and Casebia Therapeutics, a joint-venture established by CRISPR Therapeut...
ALDEX GS™ Tablets
ALDEX GS DMTablets
Metal complexes that catalyze inactivation and degradation of biomolecular targets can be developed into novel therapeutics (catalytic metallodrugs) against a variety of diseases. Despite recent advan...
The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...
Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System
The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...
The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...
This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...
Welcome at the CMBI, which is short for Centre for Molecular and Biomolecular Informatics. The centre performs research and education, and provides services in bioinformatics and cheminformatics.
The Association of Biomolecular Resource Facilities is an international society dedicated to advancing core and research biotechnology laboratories through research, communication, and education.
An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technolo...
Affigen (www.affigen.com) develops tumor-identifying therapeutics that target cell lineage-specific tumor proteins in certain incurable cancers. The Company's growing team ...
A platform nanoparticulate technology for biomolecular delivery in a broad range of industrial, personal use, and biomedical applications.
We have published hundreds of BioMolecular Therapeutics, Inc. news stories on BioPortfolio along with dozens of BioMolecular Therapeutics, Inc. Clinical Trials and PubMed Articles about BioMolecular Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMolecular Therapeutics, Inc. Companies in our database. You can also find out about relevant BioMolecular Therapeutics, Inc. Drugs and Medications on this site too.